In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by Peter Lucas, M.D., Ph.D., vice chair of Research for the Department of Laboratory Medicine and Pathology (DLMP) at Mayo Clinic.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by Eric Hsi, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic.
Maryam Shahi, M.D., explains how Mayo Clinic Laboratories' unique biomarker test (TEST ID: AFOLR) determines which patients would likely benefit from a new treatment for recurrent epithelial ovarian cancer. Disease recurrence is common, and about one-third of patients respond to the new medication.
Reserve your spot for the 24th International Surgical Pathology Symposium, which will take place May 7–10, 2024, at the Intercontinental in Dublin, Ireland. This conference will address common and uncommon diagnostic dilemmas encountered within surgical pathology practice.
The 24th International Surgical Pathology Symposium is an exciting opportunity for practicing surgical pathologists to expand their knowledge and skills. Presented by Mayo Clinic Laboratories, this four-day conference will address common and uncommon diagnostic dilemmas encountered within surgical pathology practice.
In a recent discovery by Mayo Clinic Laboratories, a novel hemoglobinopathy category was identified and termed epsilon gamma thalassemia. The first instance of the disorder was found in 2017 when an obstetric patient underwent a routine screening for blood-related illnesses such as sickle cell disease and thalassemia. Upon completion of additional tests, doctors found an abnormality they had never seen before.
Almost four years ago, Mayo Clinic launched the Digital Pathology Program, a major pathology initiative. Phase 2 of this multi-phase rollout has recently been completed, which involved the implementation of cutting-edge digital equipment and software, and converting glass slides of patient samples into digital images. The conversion enables pathologists and laboratory technologists to view, store, retrieve, and share medical images more universally, without waiting for glass slides to be retrieved and delivered. This has significantly improved patient care because pathologists can now discuss cases with clinicians and surgeons in real time.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, and William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, discuss how representation and advocacy make a difference in regulatory outcomes.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, sits down with Joaquin Garcia, M.D., chair of Mayo Clinic’s Division of Anatomic Pathology and digital pathology program to discuss how the advent of digital pathology is changing patient care at Mayo Clinic.
Joseph Maleszewski, M.D., and Marie-Christine Aubry, M.D., explain how Mayo Clinic Laboratory can provide definitive diagnosis of primary ciliary dyskinesia (PCD). Mayo Clinic's expertise and technology have earned the laboratory's designation as the sole center of excellence for diagnosing this rare respiratory disorder.
Darci Block, Ph.D., of the Department of Laboratory Medicine and Pathology at Mayo Clinic, authored an article in the American Association for Clinical Chemistry’s (AACC) Clinical Laboratory News highlighting hurdles in body fluid testing.
Over the course of two days, Mayo Clinic’s 2022 Breast Cancer Care: Innovation, Disruptive Technologies and Early Adopters educational conference will bring you up to speed on the new therapeutics, technologies and techniques that could change the way you provide breast cancer care.
Mayo Clinic is the first and only PCD Foundation accredited center for the diagnosis of primary ciliary dyskinesia, a rare and debilitating lung disease.